CLINICAL TRIALS

Advancement of clinical and microbiological research for diagnosis and treatment effects.

LABORATORY SERVICES

Standardised clinical trial services in pre-analytical, analytical and post-analytical procedures.

DATA MANAGEMENT

Initiation and deployment of clinical trials data base management systems.

GOOD CLINICAL PRACTICE

Accredited theory based modules with practical training for clinicians and support staff.

Welcome to TASK!

About Us

TASK is a clinical research organisation based in Cape Town, South Africa with a focus on performing clinical trials. TASK provides assistance to efficiently conduct studies for diagnosis, treatment or prevention of tuberculosis, as well as other prevalent diseases such as asthma, osteoarthritis and vaccine studies, where new and improved treatments are urgently needed.

The company was founded in 2005 by Prof. Andreas Diacon to accelerate the development and evaluation of novel anti-tuberculosis drugs. TASK mainly collaborates with international NGOs, government funded consortia, academic centers and pharmaceutical companies on various drug development projects.

TASK now employs over 150 staff members, has invested in state of the art bio-safety level 3 laboratory capacity as well as a network of clinical sites in Cape Town and the Western Cape.

 

Vision and Mission

Better healthcare starts with us. TASK provides a platform for the development of novelties in healthcare that benefit the community.

Values

We want to be excellent. Do our work right and on time, every time. We own up, learn, and improve each day. We are TASK.

Resources

The Western Cape is home to diverse population groups, this coupled with first world infrastructure and TASK clinical expertise and experience, provides an ideal setting for clinical research.

We believe in community

COMMUNITY ENGAGEMENT PROJECTS

Current Treatment Stand

Furthermore, TB is increasingly becoming resistant to the current treatment

New TB Drugs In The Pipeline

There are currently at least 12 drugs in various stages of clinical evaluation for TB

Clinical Studies

We do many clinical studies, click to read more about it.

Asthma Trials

We are looking for children and adults to participate.

TB Research

Tuberculosis is one of the major causes of disability and death worldwide.

TB RESEARCH

Tuberculosis is one of the major causes of disability and death worldwide.
TB is currently the leading cause of death from a single infectious agent (above HIV/AIDS). In 2017, TB caused an estimated 1.6 million deaths worldwide. In the same year an estimated 10.0 million people developed TB globally (WHO Global TB report, 2018). South Africa remains one of the World Health Organization’s 30 high TB-burden countries contributing 3% to the global TB burden, with close to 800 people out of every 100 000 of the country’s population developing a new case of TB yearly (South African Health Review, 2018).
TB is a leading cause of death for people infected with HIV.
In 2015, 1 in 3 HIV deaths was due to TB. Globally in 2014, an estimated 480, 000 people developed multidrug-resistant TB (MDR-TB).
TASK is part of the global research community that is committed to finding new ways to better understand, diagnose, treat, and ultimately prevent TB.

RECENT NEWS & EVENTS

TASK Lab Tech presenting to the CAB

Recently one of TASK’s laboratory technologists presented a slide show on “the role of the laboratory in clinical research” to an enthusiastic audience of Community Advisory Board (CAB) members. The CAB where eager to learn and ask questions, this to relay information back to the communities in which they serve. This is their critical and primary…

Read more

WORLD AIDS Day commemoration 2019

🎗The day started with a Commemoration programme at Delft CHC. Talks by HIV & AIDS Activists, Health Professionals before a moment of silence and a candlelight ceremony to remember those who have passed on because of AIDS. 🎗 The second part was to get into the community and encourage them to know their status and…

Read more

BTZ043 press release

PRESS RELEASE Tuberculosis: New drug substance BTZ-043 is being tested on patients for the first time A crucial step in the development of a promising new drug which has also proven to be effective against multidrug-resistant pathogens in preclinical tests The Tropical Institute at the Hospital of the Ludwig-Maximilians-Univer- sity (LMU) Munich is currently conducting…

Read more